Journal of Clinical Oncology
Articles in this Issue
Efficacy of ferric carboxymaltose on anemia in patients with gastrointestinal cancer: A retrospective study.
825 Background: Patients with gastrointestinal (GI) cancer often develop anemia due to the disease itself or as a treatmen...
TRIUNITE-02: A phase 2, open-label, randomized study of neoadjuvant CAPEOX plus tislelizumab and chidamide versus CAPEOX alone in previously untreated, resectable, locally advanced mismatch repair-proficient/microsatellite stable colon cancer.
TPS261 Background: The perioperative management of LACC aims to reduce the risk of local recurrence and distant metastasis...
Treatment patterns and outcomes of patients diagnosed with metastatic pancreatic adenocarcinoma.
685 Background: About 50% of patients with pancreatic cancer have metastatic disease at diagnosis, at which point the 5-ye...
Decoding molecular, clinico-pathological, and outcome differences between early-onset (EO, <50 years) and late-onset (LO, ≥50 years) mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer (CRC): Insights from real-world data.
19 Background: The incidence of EO CRC is rising globally. While clinico-molecular features of EO mismatch repair proficie...
Racial and ethnic differences in pancreatic cancer survival and treatment at a high-volume center.
662 Background: Survival disparities by race and ethnicity in pancreatic cancer are often attributed to delayed access to...
Prediction of in-hospital mortality among pancreatic cancer patients using modified Cancer Frailty Assessment Score Tool: A National Inpatient Sample database study from 2016-2022.
789 Background: Pancreatic cancer impose major burden on healthcare resource utilization in oncology care. We employed the...
Genomic and transcriptomic predictors of early vs late recurrence after curative intent surgery in patients with pancreatic cancer.
754 Background: Pancreatic ductal adenocarcinoma (PDAC) is the third deadliest malignancy with most patients (pts) present...
Online patient and caregiver conversations focused on neuroendocrine neoplasms (NENs): A global thematic analysis.
645 Background: NENs are a heterogeneous group of malignancies with complex care needs. Patients and caregivers increasing...
Results of a phase 2 study of a novel DLL4-VEGF, a bispecific antibody, tovecimig (CTX-009), as a monotherapy in patients with refractory metastatic colorectal cancer (COMPANION-003).
125 Background: Tovecimig is a recombinant bispecific antibody that simultaneously blocks the delta-like ligand-4 (DLL4) a...
Can distal gastrectomy be considered a treatment option for localized type 4 gastric cancer?
408 Background: Borrmann Type 4 gastric cancer is defined as diffuse infiltrative type cancer without ulceration. This typ...
Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel as first-line treatment for patients with metastatic pancreatic cancer (ACCENT trial): Phase 2a results.
735 Background: Narmafotinib is a potent and selective, orally bioavailable inhibitor of Focal Adhesion Kinase (FAK), a no...
Real-world efficacy of gemcitabine plus cisplatin with immune checkpoint inhibitor and with S-1 in biliary tract cancer: A multicenter retrospective study.
550 Background: Biliary tract cancer (BTC) is an aggressive malignancy with limited treatment options and a poor prognosis...
Effect of pancreatic parenchymal fibrosis on long-term outcomes in pancreatic cancer patients measured using AI-guided MRI image.
660 Background: Pancreatic parenchymal fibrosis has been reported as a risk factor for surgical complications and a progno...
ARB1002, a potential first-in-class CDH17-specific ADC, for treatment of pancreatic and other gastrointestinal cancers.
736 Background: Pancreatic cancer is an aggressive tumors resistant to standard therapies, due to lack of early detection...
Pancreatic acinar cell carcinoma (PACC): A comparative genomic landscape study.
746 Background: PACC is a rare subtype accounting for ~1% of all exocrine pancreatic neoplasms and remains understudied co...
Neoadjuvant, adjuvant and perioperative systemic therapies in gastric and gastroesophageal junction adenocarcinoma: A network meta-analysis of randomized controlled trials.
390 Background: Surgery alone often provides suboptimal outcomes for patients with locally advanced (LA) gastric and gastr...
Survival outcomes and toxicity of stereotactic MR guided adaptive radiation therapy (SMART) in locally advanced pancreatic cancer.
787 Background: NRG GI 011, a study randomizing patients with locally advanced pancreatic cancer (LAPC) with and without a...
Enhancing personalized, evidence-based care for veterans with hepatocellular carcinoma (HCC): Insights from a team-based quality improvement initiative.
531 Background: Hepatocellular Carcinoma (HCC) is a major health challenge among Veterans, necessitating a nuanced approac...
Closing the documentation gap: CDI physician advisor education and its effect on quality metrics.
104 Background: Inpatient mortality is a powerful patient safety benchmark and is a key performance metric used as a measu...
Comparison of chemotherapy plus PD-1 inhibitor with chemoradiotherapy for metastatic ESCC patients with severe dysphagia.
318 Background: Dysphagia is a common symptom in patients (pts) with metastatic esophageal squamous cell carcinoma (ESCC)....
A multicenter phase 1b/2 trial of gemcitabine, cisplatin, nab-paclitaxel, and tislelizumab (GENTIS) in treatment-naïve patients with locally advanced or metastatic biliary tract cancer.
TPS616 Background: Biliary tract cancers (BTCs) are aggressive malignancies with limited treatment options and poor progno...
Comparative safety of futibatinib vs pemigatinib in metastatic cholangiocarcinoma: FAERS-based analysis.
512 Background: Fibroblast Growth Factor Receptor (FGFR) inhibitors have transformed treatment for patients with metastati...
Efficacy and safety of durvalumab plus gemcitabine/cisplatin in combined hepatocellular-cholangiocarcinoma versus cholangiocarcinoma.
499 Background: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer characterized by feat...
Clinicopathological factors related to survival in advanced pancreatic cancer in elderly patients at the American-British Cowdray Medical Center.
701 Background: Although the majority of pancreatic cancer (PC) patients worldwide are elderly, this population remains un...
TMaC Trial: A randomized, single-blinded, sham-controlled study evaluating effectiveness of repetitive transcranial magnetic stimulation for painful chemotherapy-induced peripheral neuropathy in colorectal cancer survivors.
TPS251 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent and debilitating complication characte...